Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neoplasma ; 70(5): 597-609, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-38053379

RESUMO

Colorectal cancer (CRC) is a malignant tumor with high morbidity and mortality. It is well-accepted that dysregulated lncRNAs are closely related to the development of CRC. In this study, the function and mechanism of RNASEH1-AS1 in CRC were investigated. RT-qPCR and western blot detected the expression of targeted genes in tissues and cells. CCK-8, clone formation, wound healing assay, and Transwell were applied to evaluate CRC cell malignant behaviors. ChIP, RIP, and RNA pull-down validated interactions among RNASEH1-AS1, H3K27ac, CBP, BUD13, and ANXA2. Nucleoplasmic separation and FISH assay determined the location of RNASEH1-AS1 in CRC cells. IHC assay was used to detect Ki-67 expression in tumor tissues from mice. RNASEH1-AS1 was highly expressed in CRC tumor tissues and cells. RNASEH1-AS1 silencing effectively suppressed the viability, proliferation, migration, and invasion of CRC cells. In addition, CBP-mediated H3K27ac increased RNASEH1-AS1 expression in CRC cells and RNASEH1-AS1 could elevate ANXA2 expression through recruiting BUD13. Furthermore, RNASEH1-AS1 silencing inhibited malignant phenotypes of CRC cells and tumor growth in mice through decreasing ANXA2 expression and inactivating the Wnt/ß-catenin pathway. Our results revealed that RNASEH1-AS1 induced by CBP-mediated H3K27ac activated Wnt/ß-catenin pathway to promote CRC progression through recruiting BUD13 to stabilize ANXA2 mRNA, which provides substantial evidence of RNASEH1-AS1 in CRC. Targeting RNASEH1-AS1 might alleviate CRC progression.


Assuntos
Neoplasias Colorretais , MicroRNAs , RNA Longo não Codificante , Animais , Camundongos , beta Catenina/metabolismo , Carcinogênese/genética , Linhagem Celular Tumoral , Movimento Celular/genética , Proliferação de Células/genética , Neoplasias Colorretais/patologia , Regulação Neoplásica da Expressão Gênica , MicroRNAs/genética , RNA Longo não Codificante/genética , RNA Longo não Codificante/metabolismo , RNA Mensageiro/genética
2.
Bioresour Technol ; 384: 129332, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37328015

RESUMO

Extravagant price and lack of high-efficiency recovery technology limited scale-up utilization of ionic liquids. Ionic liquids recovery with electrodialysis-based techniques has caught wide concern due to membrane-based characteristic. Economical assessment for electrodialysis-based ionic liquid recovery and recycling in biomass processing was performed by determining influence of equipment-related and financial-related factors with sensitivity analysis for each factor. Overall recovery cost of 1-ethyl-3-methylimidazolium acetate, choline acetate, 1-butyl-3-methylimidazolium hydrogen sulphate and 1-ethyl-3-methylimidazolium hydrogen sulfate varied within 0.75-1.96 $/Kg, 0.99-3.00 $/Kg, 1.37-2.74 $/Kg and 1.15-2.89 $/Kg when factors changed within investigated range. Fold of membrane cost, factor of membrane stack cost, factor of auxiliary equipment cost, factor of annual maintenance cost and annual interest rate of loan were positively related with recovery cost. While percentage of annual elapsed time and loan period were negatively correlated with recovery cost. Economical assessment confirmed economic efficiency of electrodialysis for ionic liquids recovery and recycling in biomass processing.


Assuntos
Líquidos Iônicos , Biomassa , Reciclagem , Acetilcolina , Hidrogênio
3.
Data Brief ; 32: 106212, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32904322

RESUMO

This paper accompanies the paper titled "Defining and predicting early recurrence in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy" presented by the same authors to the European Journal of Surgical Oncology [1]. The present article describes the relevant clinical data of patterns of initial recurrence after curative surgery for rectal cancer with neoadjuvant therapy. This data was collected from the hospital records, Chinese Population Registration and Health Insurance System.

4.
Eur J Surg Oncol ; 46(11): 2057-2063, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32782202

RESUMO

BACKGROUND: The definition of "early recurrence (ER)" after rectal cancer surgery is currently unclear. OBJECTIVE: To determine an evidence-based cut-off to distinguish early and late recurrence (LR) for patients with rectal cancer and compare the clinicopathological factors between the two groups. METHODS: Patients who underwent neoadjuvant chemoradiotherapy (nCRT) and radical resection for locally advanced rectal cancer were included. A minimum p-value approach was used to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into ER and LR groups based on overall survival. A logistic regression model was used to assess risk factors for ER. RESULTS: A total of 763 patients were included, of which 167 (21.9%) experienced recurrence. The optimal cut-off value of recurrence-free survival to differentiate between ER (n = 125, 74.9%) and LR (n = 42, 25.1%) was 24 months (P = 0.000001). The median postrecurrence survival of ER and LR was 12 months and 22 months, respectively (p = 0.028). The most common recurrent sites in patients with ER and LR were lung metastases, the incidence of liver metastases, however, differed considerably in ER and LR (27.2% vs 9.5%, P = 0.019). Risk factors including elevated preoperative carcinoembryonic antigen (CEA), higher ypTNM stage, positive circumferential resection margin (CRM), and perineural invasion were significantly associated with ER. CONCLUSION: A recurrence-free interval of 24 months is the optimal cut-off value for defining ER versus LR. Elevated preoperative CEA, higher ypTNM staging, positive CRM, and perineural invasion were associated with ER of locally advanced rectal cancer.


Assuntos
Carcinoma/terapia , Quimiorradioterapia , Neoplasias Hepáticas/secundário , Neoplasias Pulmonares/secundário , Terapia Neoadjuvante , Recidiva Local de Neoplasia/epidemiologia , Protectomia , Neoplasias Retais/terapia , Adulto , Idoso , Antígeno Carcinoembrionário/sangue , Carcinoma/sangue , Carcinoma/patologia , Carcinoma/secundário , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Margens de Excisão , Pessoa de Meia-Idade , Invasividade Neoplásica , Estadiamento de Neoplasias , Prognóstico , Neoplasias Retais/sangue , Neoplasias Retais/patologia , Fatores de Risco , Fatores de Tempo
5.
World J Surg ; 44(9): 3149-3157, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-32415467

RESUMO

AIM: This study aimed to evaluate whether earlier initiation (< 4 weeks) of adjuvant chemotherapy (ACT) confer any oncological benefits for locally advanced rectal cancer (LARC) patients undergoing neoadjuvant chemoradiotherapy (nCRT) and radical surgery. METHOD: Clinicopathological and survival outcomes were compared. Propensity score matching (PSM) was performed to adjust for differences between groups. Cox regression analysis was performed to evaluate the impact of earlier ACT initiation on overall survival (OS) and disease-free survival (DFS). RESULTS: Totally, 443 eligible patients were included. More laparoscopic surgeries, less postoperative complications, and more ACT completion were observed in patients whose ACT was initiated within 4 weeks after surgery (all P < 0.001). With a mean follow-up of 59 months, the 5-year OS and DFS rate was 89.8% and 82.0% in the early group, significantly higher than 81.6% and 73.1% in the late group (P = 0.007, and P = 0.022, respectively). After PSM, the 5-year OS and DFS rate was 90.9% and 84.4% in the early group, significantly higher than 83.4% and 68.8% in the late group (P = 0.047, and P = 0.017, respectively). Cox regression analysis demonstrated that time to ACT initiation (early vs. late, HR = 0.486, P = 0.008) was independently associated with OS. CONCLUSION: Early initiation of ACT (<4 weeks) confers a survival benefit, and is an independent prognostic factor of OS in LARC patients following nCRT. Further investigations are needed to define the role of earlier initiation of ACT in patients with LARC after nCRT.


Assuntos
Antineoplásicos/uso terapêutico , Estadiamento de Neoplasias , Protectomia/métodos , Pontuação de Propensão , Neoplasias Retais/terapia , Quimiorradioterapia , Quimioterapia Adjuvante/métodos , Intervalo Livre de Doença , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Terapia Neoadjuvante/métodos , Segunda Neoplasia Primária , Neoplasias Retais/diagnóstico , Estudos Retrospectivos
6.
Int J Clin Oncol ; 25(7): 1299-1307, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32274615

RESUMO

OBJECTIVE: This study aimed to evaluate the predictive value of hematological inflammation-based indexes in the treatment response to neoadjuvant chemoradiotherapy (NCRT) in rectal mucinous adenocarcinomas (MACs). METHODS: Patients with rectal MACs undergoing NCRT and curative resection were included. Inflammation-based indexes such as systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index (PNI) were calculated. Receiver operator characteristics analysis was used to determine the optimal cutoff points. Multivariable logistic analysis identified predictors of good response to NCRT. A nomogram was developed and validated internally. RESULTS: A total of 100 patients met the inclusion criteria, with 32 patients developing good response (tumor regression grade, TRG 0 + 1) to NCRT. Lower pre-treatment SII, NLR, and PLR levels were associated with a higher probability of good response to NCRT (P = 0.025, P < 0.001, P = 0.003, respectively), and a higher pre-treatment PNI level was associated with a higher probability of good response to NCRT (P = 0.005). Logistic regression analysis demonstrated that tumor size (< 3 cm, OR = 5.489, P = 0.025), pre-treatment NLR level (< 3.05, OR = 4.025, P = 0.028), pre-treatment PLR level (< 145.98, OR = 4.337, P = 0.038), and pre-treatment PNI level (≥ 41.32, OR = 3.477, P = 0.039) were independent predictors of good response to NCRT. A nomogram was developed with a C-index of 0.827. CONCLUSION: Hematological inflammation-based indexes, in terms of pre-treatment NLR, PLR, and PNI levels, can help in predicting the treatment response to NCRT for rectal MACs.


Assuntos
Adenocarcinoma Mucinoso/terapia , Inflamação/sangue , Neoplasias Retais/terapia , Adenocarcinoma Mucinoso/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Quimiorradioterapia , Feminino , Humanos , Inflamação/etiologia , Inflamação/patologia , Linfócitos/patologia , Masculino , Pessoa de Meia-Idade , Terapia Neoadjuvante , Neutrófilos/patologia , Nomogramas , Avaliação Nutricional , Contagem de Plaquetas , Neoplasias Retais/sangue , Reto/patologia , Estudos Retrospectivos , Resultado do Tratamento
7.
World J Surg ; 44(6): 1975-1984, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32020327

RESUMO

BACKGROUND: Coagulation and inflammation play important roles in tumor progression. This study aimed to explore the prognostic impact of combined analysis of fibrinogen and neutrophil-to-lymphocyte (NLR) ratio (F-NLR score) in locally advanced rectal cancer (LARC) receiving preoperative chemoradiotherapy (pCRT) and radical surgery. METHOD: Totally 317 patients were included. X-tile analysis was used to determine the optimal cutoff values of preoperative fibrinogen and NLR. F-NLR scores were defined as 2 (both high fibrinogen and NLR), 1 (one of these abnormalities), or 0 (neither abnormality). Time-dependent ROC analysis was used to evaluate the predictive accuracy of fibrinogen, NLR, and F-NLR score. Cox regression analysis was performed to evaluate the prognostic impact of the F-NLR score. A predictive nomogram for disease-free survival (DFS) was developed and validated internally. RESULTS: One hundred and seventeen (36.9%), 156 (49.2%), and 44 (13.9%) patients had F-NLR score of 0, 1, and 2, respectively. Higher F-NLR score was associated with poorly differentiated tumors, deeper tumor invasion, lymph node metastasis, and more advanced pTNM stage (all P < 0.05). The 5-year OS rates in the F-NLR 0, 1, and 2 groups were 93.6%, 87.3%, and 68.4%, respectively (P < 0.001), while the 5-year DFS rates were 91.8%, 76.8%, and 56.1%, respectively (P < 0.001). Cox regression analysis demonstrated that F-NLR score (F-NLR 1, HR = 2.021, P = 0.046; F-NLR 2, HR = 3.356, P = 0.002), pTNM stage III (HR = 3.109, P = 0.009), and circumferential resection margin (CRM) involvement (HR = 3.120, P = 0.021) were independently associated with DFS. A nomogram for DFS was developed (C-index 0.708). CONCLUSION: F-NLR score is a promising predictor for disease recurrence in LARC patients after pCRT.


Assuntos
Fibrinogênio/metabolismo , Linfócitos , Neutrófilos , Neoplasias Retais/sangue , Neoplasias Retais/terapia , Adulto , Idoso , Biomarcadores/sangue , Intervalo Livre de Doença , Feminino , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Terapia Neoadjuvante , Gradação de Tumores , Invasividade Neoplásica , Estadiamento de Neoplasias , Nomogramas , Valor Preditivo dos Testes , Período Pré-Operatório , Modelos de Riscos Proporcionais , Curva ROC , Neoplasias Retais/patologia , Taxa de Sobrevida
8.
Future Oncol ; 16(8): 339-351, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32067478

RESUMO

Aim: To explore the impact of preoperative the albumin-to-globulin ratio (AGR) and the prognostic nutritional index (PNI) on prognosis in rectal mucinous adenocarcinoma (MAC). Methods: A total of 128 patients were included. Results: According to the X-tile analysis, cutoff values of AGR and PNI were 1.1 and 43.8. Preoperative AGR (p = 0.041), preoperative PNI (p = 0.036) and pTNM stage (p = 0.003) were independently associated with overall survival in rectal MAC patients. Distance from the anal verge (p = 0.005), preoperative AGR (p = 0.021), preoperative PNI (p = 0.007) and pTNM stage (p < 0.001) were significantly associated with disease-free survival in rectal MAC patients. Nomograms for overall survival and disease-free survival were developed (C-index: 0.739 and 0.764). Conclusion: Preoperative AGR and PNI can act as effective predictors for survival for rectal MAC patients.


Assuntos
Adenocarcinoma Mucinoso/imunologia , Adenocarcinoma Mucinoso/mortalidade , Imunidade , Estado Nutricional , Neoplasias Retais/imunologia , Neoplasias Retais/mortalidade , Adenocarcinoma Mucinoso/patologia , Adulto , Idoso , Biomarcadores , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Avaliação Nutricional , Prognóstico , Modelos de Riscos Proporcionais , Neoplasias Retais/patologia , Albumina Sérica Humana , Soroglobulinas , Análise de Sobrevida
9.
J Gastrointest Surg ; 23(5): 1006-1014, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30187336

RESUMO

PURPOSE: This study aimed to investigate the prognostic significance of negative lymph nodes (NLNs) for ypN+ rectal cancer after neoadjuvant chemoradiotherapy (nCRT) and radical surgery and to construct a nomogram predicting disease-free survival (DFS). METHOD: One hundred fifty-eight eligible patients were included. X-tile analysis was performed to determine cutoff values of NLNs. Clinicopathological and survival outcomes were compared. A Cox regression analysis was performed to identify prognostic factors of DFS. A nomogram was constructed and validated internally. RESULTS: X-tile analysis identified cutoff values of 4 and 16 in terms of DFS (χ2 = 8.129, p = 0.017). The 3-year DFS rates for low (≤ 4), middle (5-16), and high (≥ 17) NLNs group was 15.2, 55.5, and 73.1%, respectively (P = 0.017). NLN count (NLNs ≥ 17, HR = 0.400, P = 0.022), IMA nodal metastasis (HR = 1.944, P = 0.025), tumor differentiation (poor/anaplastic, HR = 1.805, P = 0.021), and ypT4 stage (HR = 7.787, P = 0.047) were independent prognostic factors of DFS. A predicting nomogram incorporating the four significant predictors was developed with a C-index of 0.64. CONCLUSION: NLN count was an independent prognostic factor of DFS in patients with ypN+ rectal cancer following nCRT. A nomogram incorporating NLN count, IMA nodal metastasis, tumor differentiation, and ypT stage could stratify rectal cancer patients with different DFS and might be helpful during clinical decision-making.


Assuntos
Linfonodos/patologia , Nomogramas , Neoplasias Retais/patologia , Neoplasias Retais/terapia , Adulto , Idoso , Quimiorradioterapia Adjuvante , Intervalo Livre de Doença , Feminino , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Terapia Neoadjuvante , Gradação de Tumores , Estadiamento de Neoplasias , Modelos de Riscos Proporcionais , Fatores de Risco , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...